Inventor · disambiguated record
Douglas Jones
Also filed as: JONES DOUGLAS · JONES DOUGLAS S · JONES DOUGLAS SCOTT · JONES II DOUGLAS S
17 granted patents·11 pending applications·97 citations·filing 1988–2023
93Inventor score
Files withUNIV LELAND STANFORD JUNIOR18COCHRAN JENNIFER R3TORQUE THERAPEUTICS INC3GIACCIA AMATO J2PETROLITE CORP1
Top patents by PatentIndex Score
28 records- 0195US11498952B2Fusion proteins comprising an engineered knottin peptide and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Nov 15, 2022·4 cites·3 claims
- 0294US12240882B2Fusion proteins comprising an engineered knottin peptide and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Mar 4, 2025·2 cites·14 claims
- 0391US8618254B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Dec 31, 2013·25 cites·8 claims
- 0488US9074192B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Jul 7, 2015·7 cites·7 claims
- 0587US11471490B2T cells surface-loaded with immunostimulatory fusion molecules and uses thereofTORQUE THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·9 cites·30 claims
- 0685US9556248B2Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonistsCOCHRAN JENNIFER R·Filed 2011·Granted Jan 31, 2017·5 cites·20 claims
- 0783US9879061B2Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2012·Granted Jan 30, 2018·4 cites·4 claims
- 0882US10844106B2Fusion proteins comprising an engineered knottin peptide and uses thereofCOCHRAN JENNIFER R·Filed 2011·Granted Nov 24, 2020·3 cites·24 claims
- 0982US8741839B2Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrinCOCHRAN JENNIFER R·Filed 2010·Granted Jun 3, 2014·5 cites·12 claims
- 1080US9441026B2Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 13, 2016·3 cites·4 claims
- 1179US11136563B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 5, 2021·1 cites·6 claims
- 1279US9266947B2Inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Feb 23, 2016·4 cites·6 claims
- 1378US9822347B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Nov 21, 2017·3 cites·3 claims
- 1478US9234021B2Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Jan 12, 2016·2 cites·2 claims
- 1573US9505822B2Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Nov 29, 2016·1 cites·9 claims
- 1673US4920141ASynergistic biocides of certain nitroimidazoles and aldehydesPETROLITE CORP·Filed 1988·Granted Apr 24, 1990·19 cites·8 claims
- 1769US2022220458A1Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 1866US2022033453A1Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonistsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 1962US2015005235A1Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3 IntegrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 2055US2019048051A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2018·Application pending·0 cites
- 2152US2025101107A1Cd8-targeted il-12 fusion proteinsREPERTOIRE IMMUNE MEDICINES INC·Filed 2023·Application pending·0 cites
- 2251US2016039896A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 2351US2018094034A1Inhibition of axl/gas6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 2450US2022008526A1Methods and compositions for cancer immunotherapyTORQUE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2547US2015315552A1Inhibition of AXL Signaling in Primary Tumor TherapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 2647US2016108378A1Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 2741US11472856B2Methods and compositions for promoting immune cell functionTORQUE THERAPEUTICS INC·Filed 2017·Granted Oct 18, 2022·0 cites·20 claims
- 2837US2016039895A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Douglas Jones files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →